RTTNews | Sep 13, 2021 10:38AM EDT

10:37 Monday, September 13, 2021 (RTTNews.com) - Shares of eFFECTOR Therapeutics, Inc. (EFTR) gained nearly 10% on Monday morning despite no stock related news to drive the shares.

EFTR is currently trading at $29.21, up $2.62 or 9.85%, on the Nasdaq.

eFFECTOR Therapeutics, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.

Read the original article on RTTNews ( https://www.rttnews.com/3225235/effector-therapeutics-shares-up-10.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved